Pharsight

Novartis Pharm patents expiration

1. Afinitor Disperz patents expiration

AFINITOR DISPERZ's oppositions filed in EPO
Can you believe AFINITOR DISPERZ received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8778962 NOVARTIS PHARM Treatment of solid tumors with rapamycin derivatives
Feb, 2022

(1 year, 7 months ago)

US8778962

(Pediatric)

NOVARTIS PHARM Treatment of solid tumors with rapamycin derivatives
Aug, 2022

(1 year, 1 month ago)

US8617598 NOVARTIS PHARM Pharmaceutical compositions comprising colloidal silicon dioxide
Sep, 2022

(1 year, 1 day ago)

US8617598

(Pediatric)

NOVARTIS PHARM Pharmaceutical compositions comprising colloidal silicon dioxide
Mar, 2023

(6 months ago)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 10, 2025

Drugs and Companies using EVEROLIMUS ingredient

Market Authorisation Date: 29 August, 2012

Treatment: Treatment of patients with tuberous sclerosis complex (tsc) who have subependymal giant cell astrocytoma (sega) that requires therapeutic intervention but cannot be curatively resected.; Adjunctive tr...

Dosage: TABLET, FOR SUSPENSION;ORAL

How can I launch a generic of AFINITOR DISPERZ before it's drug patent expiration?
More Information on Dosage

AFINITOR DISPERZ family patents

Family Patents

2. Tabrecta patents expiration

TABRECTA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8461330 NOVARTIS PHARM Imidazotriazines and imidazopyrimidines as kinase inhibitors
Nov, 2027

(4 years from now)

US7767675 NOVARTIS PHARM Imidazotriazines and imidazopyrimidines as kinase inhibitors
Nov, 2027

(4 years from now)

US8420645 NOVARTIS PHARM Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
Jun, 2031

(7 years from now)

US10596178 NOVARTIS PHARM Tablet formulation of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide
Jul, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8901123 NOVARTIS PHARM Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-B][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
May, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 6, 2025
Orphan Drug Exclusivity (ODE) May 6, 2027

Drugs and Companies using CAPMATINIB HYDROCHLORIDE ingredient

NCE-1 date: 2024-05-06

Market Authorisation Date: 06 May, 2020

Treatment: Use for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with a mesenchymal-epithelial transition (met) exon 14 skipping mutation

Dosage: TABLET;ORAL

More Information on Dosage

TABRECTA family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic